A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01198418 |
Recruitment Status
:
Completed
First Posted
: September 10, 2010
Last Update Posted
: April 2, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sexually Transmitted Infections HIV Infections | Behavioral: Experimental | Phase 1 Phase 2 |
Design: CCTG 592 is a randomized, controlled study that will compare the efficacy of web-based intervention to reduce high-risk sexual behavior by persons living with HIV AIDS (PLWH).
Duration: 48 weeks
Sample Size: 200 subjects (100 per arm) that will be randomized
Study Population: HIV-1-infected men who have sex with men (MSM) at least 18 years of age who have a recent history of transmission risk behavior.
Stratification: Subjects will be stratified based upon their baseline antiretroviral use, whether they have a home computer and by site.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 181 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Randomized Controlled Clinical Trial of an Internet-based Prevention Intervention to Reduce STI in High-risk HIV Infected MSM |
Study Start Date : | November 2010 |
Actual Primary Completion Date : | August 2013 |
Actual Study Completion Date : | August 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Internet-based counseling |
Behavioral: Experimental
Internet-based intervention that assesses transmission risk and provides prevention messages
|
No Intervention: Survey Alone |
- STI incidence [ Time Frame: Baseline and follow-up visits every 3 months ]
- To compare the composite STI incidence of syphilis or Chlamydia trachomatis (CT) or Neisseria gonorrhea (GC) at any mucosal site among sexually active HIV-infected men during 12 months participation in an Internet risk reduction intervention compared to those that receive a survey instrument alone.
- To compare the incidence of nonspecific urethritis by urinalysis and testing for Mycoplasma genitalum and trichomonas sp. among sexually active HIV-infected men during 12 months participation in an Internet risk reduction intervention compared to those that receive a survey instrument alone.
- Evaluate risk factors of STIs [ Time Frame: Baseline, follow-up visits every 3 months ]
- Compare:a)self reported levels of unsafe sex among HIV-infected men b)intention to start ARV among HIV-infected men not currently on ARV will increase during 12 mos. participation in an internet risk reduction intervention compared to survey instrument alone
- Compare self-reported among HIV-infected men during 12 mos. participation as measured by those reporting 100% disclosure in an internet risk reduction intervention compared to survey instrument alone
- Collect genital tract secretions of semen for future study

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 infection, as documented by any licensed screening antibody test, such as ELISA, and confirmed by a second antibody test, such as Western blot, or detectable plasma HIV-1 RNA at any time prior to study entry. If an ELISA or Western Blot are not available, HIV infection may be documented by two HIV RNA values > 2000 copies/mL, drawn at least 24 hours apart. The HIV RNA assays should have been run at a CLIA approved laboratory or equivalent.
- 18 years of age or older.
- Male.
- At least one of the following:
- An HIV negative or unknown status sexual partner in the past three months.
- A sexually transmitted disease in the past 1 year (other than HIV).
- More than 2 male partners in past year.
- Unprotected anal sex in past 3 month.
- Capable of signing written informed consent.
- Read and comprehend English
- Adequate computer skills for study.
Exclusion Criteria:
- Uncontrolled psychiatric condition.
- Drug or alcohol users with use that in the opinion of the investigator, would limit follow-up and adequate consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01198418
United States, California | |
University of Southern California | |
Los Angeles, California, United States, 90033 | |
University of California, San Diego | |
San Diego, California, United States, 92103 | |
University of California, Los Angeles (Harbor) | |
Torrance, California, United States, 90502 |
Study Chair: | Sheldon Morris, MD, MPh | California Collaborative Treatment Group | |
Study Chair: | Joel Milam, PhD | California Collaborative Treatment Group |
Additional Information:
Responsible Party: | California Collaborative Treatment Group |
ClinicalTrials.gov Identifier: | NCT01198418 History of Changes |
Other Study ID Numbers: |
CCTG 592 |
First Posted: | September 10, 2010 Key Record Dates |
Last Update Posted: | April 2, 2014 |
Last Verified: | March 2014 |
Keywords provided by California Collaborative Treatment Group:
STI MSM HIV Prevention Men having sex with men |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Immune System Diseases Genital Diseases, Male Genital Diseases, Female |